2-(4-(4-Fluorophenyl)-5-(2-(3-methylbutan-2-ylamino)pyridin-4-yl)-1H-imidazol-2-ylthio)ethanol

ID: ALA524174

Chembl Id: CHEMBL524174

PubChem CID: 24805930

Max Phase: Preclinical

Molecular Formula: C21H25FN4OS

Molecular Weight: 400.52

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)C(C)Nc1cc(-c2[nH]c(SCCO)nc2-c2ccc(F)cc2)ccn1

Standard InChI:  InChI=1S/C21H25FN4OS/c1-13(2)14(3)24-18-12-16(8-9-23-18)20-19(15-4-6-17(22)7-5-15)25-21(26-20)28-11-10-27/h4-9,12-14,27H,10-11H2,1-3H3,(H,23,24)(H,25,26)

Standard InChI Key:  WWSBAAXRYHTMOX-UHFFFAOYSA-N

Associated Targets(Human)

MAPK14 Tchem MAP kinase p38 alpha (12866 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Blood (2950 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAPK10 Tchem c-Jun N-terminal kinase 3 (3396 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 400.52Molecular Weight (Monoisotopic): 400.1733AlogP: 4.82#Rotatable Bonds: 8
Polar Surface Area: 73.83Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 10.92CX Basic pKa: 6.36CX LogP: 4.47CX LogD: 4.43
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.47Np Likeness Score: -1.32

References

1. Pierre Koch, Christiane Bäuerlein, Hartmut Jank, Stefan Laufer..  (2008)  Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles.,  51  (18): [PMID:18763757] [10.1021/jm800373t]
2. Ahamad S, Bhat SA..  (2022)  The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.,  65  (24.0): [PMID:36490325] [10.1021/acs.jmedchem.2c00799]

Source